Shenyang Xiehe Biopharmaceutical

Shenyang Xiehe Biopharmaceutical is a prominent Chinese biotechnology firm focused on the development and commercialization of superantigen-based therapies. The company is a pioneer in utilizing Staphylococcal Enterotoxin C (SEC) as a biological response modifier for cancer treatment and immune system enhancement. Its flagship product, a highly agglutinated SEC injection, is widely used in China as an adjuvant therapy for malignant tumors and to treat leukopenia caused by radiotherapy or chemotherapy. Beyond oncology, the company leverages its proprietary superantigen platform to explore treatments for autoimmune diseases and infectious diseases. Shenyang Xiehe maintains extensive GMP-certified production lines and a robust research infrastructure in Shenyang. The company's work is centered on the Superantigen theory, which aims to activate a large number of T-cells to mount a potent immune response against pathogens and tumors.